Files Definitive Proxy Statement for 2025 Annual Meeting of Stockholders Urges Stockholders to Vote “FOR” BOTH Neuphoria Therapeutics Nominees on WHITE Proxy Card BURLINGTON, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued a letter to its stockholders regarding Neuphoria’s 2025 Annual M ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - Atkore Inc. reported a net sales of $2.9 billion for fiscal 2025, marking a decrease of 11.0% compared to the previous year, primarily due to lower average selling prices and divestitures [4][16][18] - The company experienced a net loss of $15.2 million for fiscal 2025, a significant decline from a net income of $472.9 million in fiscal 2024, driven by lower operating income [18][19] - Adjusted EBITDA for fiscal 2025 decreased by 49.9% to $386.4 million, reflecting the impact of reduced sales and increased costs [19] Fourth Quarter Highlights - In Q4 2025, net sales were $752.0 million, down 4.6% from $788.3 million in Q4 2024, primarily due to lower average selling prices [6][7] - The company reported a net loss of $54.4 million in Q4 2025, compared to a net income of $73.1 million in the same quarter of the previous year [9][11] - Adjusted EBITDA for Q4 2025 was $70.9 million, a decrease of 49.4% from $140.1 million in Q4 2024 [10][13] Segment Performance - Electrical segment net sales decreased by 8.1% to $518.9 million in Q4 2025, attributed to lower average selling prices and divestitures [12] - Safety & Infrastructure segment net sales increased by 4.0% to $233.4 million in Q4 2025, driven by higher volumes [14][15] Financial Metrics - Gross profit for Q4 2025 was $147.8 million, down from $216.1 million in Q4 2024, with gross margins decreasing from 27.4% to 19.7% [8][36] - The company repurchased $100.0 million in outstanding shares and paid dividends totaling $44.2 million during fiscal 2025 [21][20] - Cash provided by operating activities was $402.8 million, while free cash flow decreased to $295.7 million for fiscal 2025 [20] Outlook - For fiscal 2026, Atkore expects net sales to be in the range of $3.0 billion to $3.1 billion, with an adjusted EBITDA outlook of $340 million to $360 million [6][23]

AUSTIN, Texas, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) today announced that its Board of Directors has initiated a review of strategic alternatives in order to explore ways to maximize shareholder value. The review will include a range of potential actions, including raising equity capital, reverse mergers, combination transactions, and the sale of all or part of the Company’s business, and other possible strategic or financial transactions. “We ...

Core Insights - Sensei Biotherapeutics, Inc. has reported its financial results for Q3 2025, highlighting a significant strategic shift in its operations [1][4][5] - The company has decided to discontinue the development of its lead product candidate, solnerstotug, and is exploring various strategic alternatives to maximize shareholder value [2][3] Financial Performance - As of September 30, 2025, the company's cash, cash equivalents, and marketable securities totaled $25.0 million, down from $41.3 million at the end of 2024 [4] - Research and Development (R&D) expenses for Q3 2025 were $2.5 million, a decrease from $4.6 million in Q3 2024, primarily due to lower personnel and facility costs [4] - General and Administrative (G&A) expenses also decreased to $2.3 million in Q3 2025 from $3.2 million in Q3 2024, attributed to reduced personnel costs [5] - The net loss for Q3 2025 was $4.6 million, compared to a net loss of $7.3 million in the same quarter of the previous year [5][8] Strategic Review and Workforce Reduction - The company has implemented a workforce reduction of approximately 65% to conserve cash while it reviews strategic alternatives [2][3] - A small team will remain to assist in exploring these alternatives and managing the cessation of development activities [3] Balance Sheet Highlights - As of September 30, 2025, total assets were reported at $27.6 million, down from $45.4 million at the end of 2024 [10] - Total liabilities decreased to $4.6 million from $7.0 million, while total stockholders' equity fell to $23.0 million from $38.4 million [10]

Core Viewpoint - Centerspace's Board of Trustees has initiated a review of the company's strategic alternatives, considering options such as a sale, merger, or continuing its independent business strategy [1][2]. Group 1: Strategic Review - The review process does not have a set timetable, and no decisions regarding potential strategic alternatives have been made at this time [2]. - Centerspace has engaged BMO Capital Markets Corp. as its financial advisor and Wachtell, Lipton, Rosen & Katz as legal counsel to assist in the review [3]. Group 2: Company Overview - Centerspace is an owner and operator of apartment communities, with a portfolio of 68 apartment communities comprising 12,941 homes across several states including Colorado, Minnesota, and Utah [4]. - The company has been recognized as a top workplace for the sixth consecutive year in 2025 by the Minneapolis Star Tribune [4].

Confirms Receipt of Unsolicited Indication of Interest and Director Nominations from Lynx1 Master Fund LP No Stockholder Action Required at This Time BURLINGTON, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (Nasdaq: NEUP), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced, as previously disclosed, the initiation of a review of strategic alternatives to advance the Company’s promising p ...

Ironwood Pharmaceuticals Q3 2025 Investor Update November 10, 2025 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our ability to execute on our mission; our strategy, business, financial position and operations; our ability to drive growth and profitability; the commercial potential of LI ...

Core Viewpoint - Paramount Skydance is interested in acquiring Warner Bros. Discovery, which is currently for sale and expected to announce its plans by mid to late December [1][2]. Group 1: Acquisition Interest - Paramount has communicated to Warner Bros. Discovery's board that its offer of $23.50 per share provides superior value to shareholders compared to the company's potential breakup [3][4]. - Warner Bros. Discovery is considering various strategic options, including splitting the company into two entities or selling some assets, with a formal sale process initiated following its June announcement [2][4]. Group 2: Strategic Review and Options - Warner Bros. Discovery is conducting a comprehensive review of strategic alternatives to maximize asset value, with the split expected to be completed by April [4][5]. - The split is viewed as a tax-efficient method for potential sales, allowing for a tax-free transaction [5]. Group 3: Market Interest - Comcast and Netflix have expressed interest in acquiring Warner Bros. Discovery's studio and streaming assets, with Comcast indicating that such an acquisition would complement its NBCUniversal business [6].

Core Viewpoint - Sensei Biotherapeutics has decided to discontinue the development of solnerstotug and is initiating a strategic review to maximize shareholder value, which may include various options such as asset sales or mergers [1][3]. Company Overview - Sensei Biotherapeutics is a clinical-stage biotechnology company focused on developing next-generation therapeutics for cancer patients [4]. Strategic Review and Workforce Reduction - The company plans to implement a workforce reduction to preserve cash, retaining a small team to assist in exploring strategic alternatives and managing the cessation of development activities [2]. - The strategic review may lead to various outcomes, including a sale of assets, licensing arrangements, or a merger, but there is no definitive timeline for this process [1][3]. Clinical Development Status - Solnerstotug has shown clinical activity in a patient population with significant unmet needs, but the company has decided not to initiate new clinical studies due to funding needs and the current capital markets environment [3].